MiRNA-200a Sensitizes Non-small-cell Lung Cancer To EGFR-TKIs By Targeting FOXC1

Objective:To investigate the role of miRNA-200a in the efficacy of targeted therapy in non-small-cell lung cancer(NSCLC)patients and its underlying mechanisms.Methods:Real-time polymerase chain reaction and Western blot were used to investigate the level of miRNA-200a and FOXC1.The MTT assay?Wound-healing and Transwell assays were performed to measure the effect of miRNA-200a and FOXC1 on cell growth,migration,invasion and other biological behaviors.Luciferase reporter assay analyzed the relationship between FOXC1 and miR-200a.Results:We found that a high level of miR-200a inhibits NSCLC cells growth,EMT,migration and invasion and increases sensitivity to gefitinib by targeting FOXC1.Furthermore,suppression of FOXC1 also inhibits cells progression and restores gefitinib resistance.Conclusion:Upregulated miRNA-200a or knockdown of FOXC1 enhanced sensitivity to gefitinib in NSCLCs.This may provide a novel effective therapeutic approach to overcome the acquisition of resistance to epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs)therapy.